About Biosynth Carbosynth
Biosynth Carbosynth is a Healthcare company based in Guildford (United Kingdom) founded in 1965, and was acquired by KKR in November 2021. It operates as a provider of drug discovery, manufacturing, supply chain, regulatory support, and other services. Biosynth Carbosynth has completed 2 acquisitions, including Aalto Bio Reagents and vivitide. Its chief executive is Urs Spitz. Its focus areas include Biopharma Outsourcing, Diversified and Biologics. Its legal entity is BIOSYNTH LIMITED. Its competitors include Novartis, Catalent, Surrozen, Curia and AmplifyBio and 4 more; 3 of its 9 listed competitors have raised funding.
Company details
Biosynth Carbosynth was established in 1965 and is headquartered in Guildford, United Kingdom. Operations focus on the pharmaceutical and chemical sectors, where drug discovery, manufacturing, supply chain management, and regulatory support services are delivered. Additional services encompass product synthesis and customization for research and industrial applications. The company serves global clients through its integrated facilities and expertise in complex molecule production.
- Headquarters Guildford, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website carbosynth.com
- Social LinkedIn X
- Acquired by KKR (Nov 2021)
- Legal Name Biosynth Limited
- Date of Incorporation 06 Apr, 2006
- Jurisdiction NEWBURY, BERKSHIRE
- Annual Revenue$23.11 M (USD)-8as on Dec 31, 2020
- Net Profit$950.18 K (USD)910as on Dec 31, 2020
- Investors
- Investments & AcquisitionsAalto Bio Reagents
& 1 more
- Acquired byKKR
(Nov 2021)
Investors in Biosynth Carbosynth
Biosynth Carbosynth has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include KKR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States |
Investor details for Biosynth Carbosynth
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biosynth Carbosynth
1 people are tracked at Biosynth Carbosynth (1 in leadership).
| Name | Role | Group |
|---|---|---|
Urs Spitz | CEO | Leadership |
Complete people profiles for Biosynth Carbosynth
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosynth Carbosynth
Biosynth Carbosynth has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aalto Bio Reagents and vivitide.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Raw materials are supplied to in-vitro diagnostics and research laboratories. | aaltobioreagents.com | Dublin, Ireland | 1978 | May 2022 | •••• | |
Drug development services for neoantigen peptides and antibodies are provided. | vivitide.com | Gardner, United States | 1983 | Mar 2022 | •••• |
Complete acquisition details for Biosynth Carbosynth
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biosynth Carbosynth
4 dated milestones of Biosynth Carbosynth across 57 years, from founding to its latest funding, stage changes and deals.
- Founded Biosynth Carbosynth is founded.
- Exit Acquired by KKR.
- Acquisition Acquires vivitide.
- Acquisition Acquires Aalto Bio Reagents.
Competitors of Biosynth Carbosynth
Biosynth Carbosynth has 9 listed competitors in our database, 3 of them funded. They include Novartis, Catalent, Surrozen, Curia and AmplifyBio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novartis.com | 1996 | Basel, Switzerland | – | 97 | R&D focused on manufacturing of drugs for multiple therapeutic areas | |
| catalent.com | 2007 | Somerset, United States | – | 9,390 | CDMO offering drug and biologics development services | |
| surrozen.com | 2016 | San Francisco, United States | $133M | 80 | Selective Wnt agonists are developed for human tissue regeneration. | |
| curiaglobal.com | 1991 | Albany, United States | – | 1,918 | Drug research, development, testing, and consulting services are provided. | |
| amplify-bio.com | 2021 | Hilliard, United States | $229.75M | – | Provides contract research, development, and manufacturing services for biologic drugs. | |
| samsungbiologics.com | 2011 | Incheon, South Korea | – | – | Contract development and manufacturing for biologics are provided. | |
| wuxibiologics.com | 2008 | Shanghai, China | – | 257 | Protein therapeutics are developed and manufactured by WuXi Biologics. | |
| biotage.com | 2009 | Uppsala, Sweden | – | – | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | |
| indapta.com | 2016 | Seattle, United States | $72.5M | – | Limited information available |
Detailed competitors of Biosynth Carbosynth
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biosynth Carbosynth
Websites that share an audience with Biosynth Carbosynth (carbosynth.com).
Websites whose visitors overlap most with Biosynth Carbosynth. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
chemfaces.com | chemfaces.com | 100% | – | #1,728,620 | – |
| chemindustry.com | 98% | 6.4K | #3,138,431 | View details | |
bepharm.com | bepharm.com | 94% | – | – | – |
| trc-canada.com | 91% | – | – | View details | |
| combi-blocks.com | 88% | – | #663,407 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Biosynth Carbosynth
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Biosynth Carbosynth (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biosynth Carbosynth
Complete news archive for Biosynth Carbosynth
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosynth Carbosynth
Biosynth Carbosynth was founded in 1965.
Biosynth Carbosynth is headquartered in Guildford, United Kingdom.
Urs Spitz is the current CEO of Biosynth Carbosynth.
Annual revenue of Biosynth Carbosynth is $23.11M as on Dec 31, 2020.
Biosynth Carbosynth was established in 1965 and is headquartered in Guildford, United Kingdom. Operations focus on the pharmaceutical and chemical sectors, where drug discovery, manufacturing, supply chain management, and regulatory support services are delivered. Additional services encompass product synthesis and customization for research and industrial applications. The company serves global clients through its integrated facilities and expertise in complex molecule production.
Biosynth Carbosynth has made 2 acquisitions, including Aalto Bio Reagents, and vivitide.
Biosynth Carbosynth has 1 investor. Key investors include KKR.
Biosynth Carbosynth operates through Biosynth Limited.
Yes. Biosynth Carbosynth was acquired by KKR in November 2021.